Psychedelic Medicine Podcast with Dr. Lynn Marie Morski

In the 200th episode of the Psychedelic Medicine Podcast, Ismail Lourido Ali, JD joins to discuss the future of psychedelic medicine. Ismail serves as MAPS Co-Executive Director and has been actively participating in the drug policy reform movement for over a decade, informed by half a lifetime of diverse personal experience with psychedelics and other substances.

In this conversation, Ismail explores the rapidly evolving landscape of psychedelic medicine, reflecting on the field's major milestones, challenges, and future possibilities. He discusses how public perception has shifted over the past decade, the role of state-level psychedelic reforms, and the tensions created by commercialization, overhype, and competing regulatory models. Much of the discussion focuses on the recent federal executive order related to psychedelic research and drug development, including what it may mean for FDA approval timelines, right-to-try access, rescheduling, and public health standards. Throughout, Ismail emphasizes that psychedelics are not a "silver bullet," but tools that require strong systems of care, thoughtful policy, and community support to be integrated responsibly into healthcare and society.

In this episode, you'll hear:

• How public attitudes toward psychedelics have shifted over the past decade
• Major milestones that expanded psychedelic policy reform beyond federal drug approval
• The promises and pitfalls of increased visibility, commercialization, and hype in the psychedelic field
• What the recent federal executive order on psychedelics actually does and does not do
• An explanation of right-to-try laws, FDA approval pathways, and the complexities of rescheduling psychedelic medicines
• Why maintaining rigorous evidentiary standards is essential for the long-term credibility of psychedelic medicine
• MAPS' vision for the future of psychedelic access, including regulated adult use, professional education, and community safety infrastructure
• How psychedelic policy reform could evolve to include broader systems of mental health care, crisis response, and social healing

Quotes:

"[Federal funding for psychedelic research] will only be so effective unless there is a massive reinvestment in mental health, harm reduction, and social services that actually ground—and one could say integrate—this medicine into like the continuum of care and the fabric of community that people are actually in." [25:07]

"Even though those of us in the psychedelic advocacy field do want to see drugs like MDMA and others be approved by the FDA for medical use in these controlled clinical settings… At the same time, we don't want medical access to be accelerated so much that it's at the expense of public health or consumer protection or an evidentiary standard that other drugs are being held to." [37:59]

"Medical professionals are not just prescribing things because they're approved. Many of them want to look at the evidence themselves. They want to look at the clinical trials. They want to understand 'is this the right choice for my patient?' But you can only know if [psychedelics] are being held to a comparable standard." [39:31]

"What's MAPS' vision for ten years from now or 40 years from now for that matter? I like to think of it as lots of on ramps and lots of off ramps. It's that people who are seeking access to psychedelics for any beneficial purpose—for their own treatment or healing, for their own spiritual growth, for their personal development, for their for improving of their relationships with their loved ones or with nature or with spirituality, whatever that cosmology is that they hold—that they have safe, responsible methods of doing so." [44:47]

Links:

Ismail on Instagram

Psychedelic Medicine Association

Porangui

In this episode, Dr. WaiFung Tsang, DClinPsy joins to discuss the intersection of psychedelics and neurodiversity. Dr. Tsang is a clinical research psychologist from Hong Kong, musician, and student of Shipibo curanderismo. He is the co-founder of Onaya, an organisation dedicated to bridging Indigenous tradition and Western science, and research advisor for psychedelic veteran charity Heroic Hearts Project.

In this conversation, Dr. Tsang explores the emerging intersection of psychedelics and neurodiversity, reframing neurodivergence as a context-dependent spectrum shaped by biology, culture, and lived experience. Drawing on clinical work with autistic individuals, veterans, and athletes, he discusses how psychedelic states may temporarily induce experiences similar to neurodivergence—heightening sensory processing, altering cognition, and expanding perception—and how these states manifest differently for neurodivergent individuals. The conversation highlights early anecdotal evidence and preliminary research suggesting potential benefits for social connection, attentional regulation, and emotional processing, while emphasizing the need for more rigorous studies. Dr. Tsang also underscores the importance of thoughtful accommodations in psychedelic settings, noting that many best practices for supporting neurodivergent participants—clear structure, sensory tools, and intentional environments—ultimately improve outcomes for all participants.

In this episode, you'll hear:

• How neurodiversity and neurodivergence are defined across cultural and clinical contexts
• The overlap between autistic sensory processing and psychedelic perceptual states
• Why psychedelics may shift autistic experiences toward more cognitive or structured processing
• Early findings on psychedelics and ADHD, including impacts on attention, impulsivity, and mental "chatter"
• The role of MDMA and other psychedelics in enhancing social connection and reducing social anxiety
• How group settings and shared ceremonies may uniquely benefit neurodivergent individuals
• Practical considerations for making psychedelic experiences more accessible and sensory-informed
• Why many "neurodivergent accommodations" are simply good practice for all participants

Quotes:

"Every autistic individual is so different and every autistic individual can be so vast and varied in their presentation." [8:57]

"For the autistic participants that come and join in our studies, we have a tendency to see a lot of more cognitive experiences or cognitive-based experiences." [15:57]

"One thing we have been finding is especially people who are autistic can benefit more from the community aspect within psychedelic experiences." [20:05]

"[In Shipibo ceremonies] there's no touching, no talking—it's very autistic friendly. You get to be in your own space. You get to be together but not be together." [35:16]

Links:

Dr. Tsang on Instagram

Dr. Tsang on LinkedIn

Onaya website

Onaya Science website

Onaya on Instagram

Onaya on LinkedIn

United Freedom Collective on Instagram

United Freedom Collective on Spotify

Heroic Hearts Project website

Psychedelic Medicine Association

Porangui

In this episode Amy Della Rocca, PMHNP joins to discuss Spravato, the FDA-approved prescription esketamine nasal spray, and its place in the field of psychedelic medicine. Amy is a psychiatric nurse practitioner and the Clinical Director of Marpa, a Spravato treatment center in New York.

In this conversation, Amy offers a grounded and practical look at Spravato as one of the most accessible forms of psychedelic medicine currently available, especially for patients with treatment-resistant depression who may be priced out of intravenous or intramuscular ketamine treatments. She explains how insurance coverage, prior authorizations, and the 2025 shift allowing Spravato to be used as monotherapy have expanded access, while also walking through what treatment actually looks like in practice - from REMS monitoring and nasal spray administration to maintenance schedules and the importance of outside therapeutic support. Throughout, Amy emphasizes that Spravato can produce a wide spectrum of psychedelic effects, that it should not be dismissed as a "lesser" medicine because it is FDA-approved or pharmaceutical, and that the most effective treatment happens in a relational container that balances medical safety, emotional support, and realistic expectations about what the medicine can and cannot do.

In this episode, you'll hear:

• What Spravato is and how it differs from other forms of ketamine treatment
• How insurance coverage, Medicaid, and copay assistance can make psychedelic care more financially accessible
• Which two diagnoses Spravato is approved to treat
• Why the 2025 approval of Spravato as a monotherapy meaningfully changed patient eligibility
• What a typical Spravato session looks like, including dosing, REMS monitoring, and maintenance treatment
• Why therapy, integration support, and external community can strongly influence treatment outcomes
• How patients' experiences can range from subtle relaxation to deeply psychedelic states
• Why stigma within psychedelic spaces can invalidate ketamine experiences - and why Amy argues that needs to change
• What makes a patient a good candidate for Spravato treatment
• How clinicians can carefully work with complex cases, including suicidality, trauma histories, and bipolar depression

Quotes:

"Generally we have Medicaid covering [Spravato treatments]. We have no co-pays on that or maybe it's a five-dollar co-pay. With some insurances, if there's a big deductible, they will have to pay the deductible like other treatments." [6:38]

"In 2025, the FDA changed that requirement [to be on an antidepressant to receive Spravato treatments]. And now Spravato is… approved for monotherapy. So, as you know, so many of the people that are coming to us are not taking daily antidepressants because they've had terrible side effects. Or… they've felt worse, it increased their [suicidal ideation] or, you know, whatever it was. And so to have them still have to take one just felt like the wrong thing to do." [8:34]

"I would say 30% of the patients continue [regular Spravato treatments] on some level—40% maybe of maintenance. And that can be every two weeks; it can be every week. There are plenty of folks that find that the glutamate activity of this medicine helps them more than anything they've ever taken and so they end up tapering off of other meds and continue to get weekly sessions with us." [14:28]

"This treatment feels, in a way, like a half-treatment without outside therapy" [15:25]

Links:

Amy on LinkedIn

Marpa Minds website

Journey Clinical website

Psychedelic Medicine Association Course: Managing Medical Risk in Patients Seeking Psilocybin Therapy

Previous episode: Ending Pill Shaming: How Psychedelics and Pharmaceuticals Can Both Support Healing with Erica Zelfand, ND

Previous episode: Ketamine Therapy Explained: The Science Behind Mental Health Treatment with Dr. Jason Wallach

Psychedelic Medicine Association

Porangui

In this episode, Michelle Weiner, DO, MPH returns to share her expertise on low-dose ketamine for chronic pain. Dr. Weiner is double board-certified in Interventional Pain Medicine, Physical Medicine, and Rehabilitation. She is founder of Neuropain Health delivering personalized integrative care treating the root cause of pain and suffering, both physical and emotional, using a multidisciplinary biopsychosocial approach with many years of clinical experience with ketamine-assisted therapy.

In this conversation, Dr. Weiner reframes chronic pain as more than a symptom of tissue damage, describing it instead as a complex sensory and emotional experience shaped by the brain, nervous system, and a person's broader life context. She explains how chronic pain can become entrenched through maladaptive neural network patterns, fear, stress, and identity-level beliefs, and argues that effective treatment must move beyond symptom suppression toward a biopsychosocial model that addresses suffering, function, and quality of life. Drawing on her clinical work, Dr. Weiner discusses how low-dose ketamine, when paired with preparation, integration, pain reprocessing therapy, somatic work, and functional movement, may help create a window of neuroplasticity that allows patients to interrupt rigid pain patterns and reconnect with their own capacity for healing.

In this episode, you'll hear:

• How Dr. Weiner understands chronic pain
• The "triple network model" of neuropsychiatric conditions and how Dr. Weiner applies this to thinking about chronic pain
• Why imaging, injections, and medications often fall short once pain has become chronic and centrally mediated
• The gate control theory of pain and how this relates to possible mechanisms of ketamine treatments of pain
• How ketamine may support chronic pain treatment by creating a temporary window of neuroplasticity that can be used for deeper therapeutic change
• What pain reprocessing therapy is and why Dr. Weiner sees it as a first-line intervention for many chronic pain conditions
• Patient stories from Dr. Weiner's practice where belief change was a key component of healing pain

Quotes:

"Over time, when [pain] becomes chronic, it's no longer trying to alter the physical body, it's actually trying to reprocess what's happening in the brain." [3:47]

"Ketamine for me started to become more interesting because I realized that this wind-up phenomenon that is so responsible for a lot of people's chronic pain can actually start to be reversed when we start using medications [like ketamine] that can change the balance of glutamate and GABA [neurotransmitters]." [14:26]

"So I just started to think, how can we use the lowest dose of ketamine to create neuroplasticity, guide them in a way that they're able to move and shift the story, and then that's how you can create long term change. [18:51]

"The key is to understand that we are our own healers. If we're not involved in actively participating in our treatment, then we're relying on someone else outside of us and that's not really a long term plan." [29:20]

"More with ketamine is definitely not better. When people feel so disconnected and so separate from themselves, they can experience more fear. And I think that's important to have that sweet spot where they're able to get that time out. They're not really feeling their pain, they're not in their ordinary mind and their conscious thoughts and they're able to have the brain connect in a different way and experience things differently, which then creates hope and allows them to really wake up and say, 'oh, there there are other options out here for me.'" [30:11]

Links:

Dr. Weiner's recent article "Treating chronic pain with low dose ketamine and adjunct therapies within a biopsychosocial approach: a case series"

Dr. Weiner's website: Neuropain Health

Dr. Weiner on Instagram

Dr. Weiner on LinkedIn

Previous episode: Ketamine-Assisted Psychotherapy for Chronic Pain with Michelle Weiner, DO, MPH

Psychedelic Medicine Association

Porangui

In this episode Dr. Simon Ruffell joins to discuss the research on ayahuasca for PTSD. Dr. Ruffell is a psychiatrist, researcher, and student of curanderismo (Amazonian shamanism) working at the intersection of Western psychiatry, traditional plant medicine, and Indigenous knowledge systems. He is Executive Director of Onaya, Lecturer in Psychology and Psychedelics at the University of Exeter, and Chief Medical Officer of MINDS, with a focus on integrative and relational approaches to healing and consciousness.

In this conversation, Dr. Ruffell explores the emerging research on ayahuasca as a treatment for PTSD, drawing on both Western scientific models and Indigenous Shipibo knowledge systems. He outlines how ayahuasca may work through mechanisms such as increased neuroplasticity, disruption of rigid predictive models, and potential epigenetic shifts related to stress and trauma, while emphasizing that these biological explanations exist alongside Indigenous understandings of "cleaning ancestral lines." Sharing preliminary findings from his ongoing research with military veterans in collaboration with Heroic Hearts Project, Dr. Ruffell discusses significant reductions in PTSD symptoms at six-month follow-up, the powerful role of community and ceremony, and the ethical complexities of studying sacred practices through Western scientific tools. He closes with a moving story of a veteran whose healing journey illustrates both the promise and the limits of psychedelic medicine when embedded in relational and cultural context.

In this episode, you'll hear:

• Western scientific theories for how ayahuasca may alleviate PTSD
• How trauma-related epigenetic changes may be transmitted across generations
• Preliminary results from Dr. Ruffell's study of ayahuasca for veterans diagnosed with PTSD
• The role of community bonding and peer support among veterans in maintaining therapeutic gains
• Why ayahuasca research in the Amazon includes a broader plant-based healing system—not just the brew itself
• How Indigenous healers interpret epigenetic findings as confirmation of longstanding ancestral frameworks
• The ethical considerations of bringing Western measurement tools (like EEG) into sacred ceremonial contexts

Quotes:

"This is what I find most interesting about our research—that it is cutting edge science but at the same time, when we conduct it with indigenous healers, we get a whole new perspective on what could be happening when it comes to interpreting the results and also making decisions of what to research as well." [14:09]

"According to measures of PTSD on the scales that we're looking at, over 80% of the participants that were scoring for PTSD before their ayahuasca retreats and no longer scoring for PTSD at that six month follow up. So it's not just immediately after the ayahuasca retreats. It's six months later. And that's super, super encouraging." [15:52]

"When we take things to the lab, one of the reasons that we might see the effect size diminishing is because we no longer have shamanism, basically, which is exerting a huge effect." [16:55]

"Traditionally what would happen is that the curandero would drink ayahuasca and the participants would just be there and the curandero would use the visions that they had with ayahuasca to look into the participants and to diagnose them. And then the healing would come through them singing their medicinal chants, which are the icaros. And then afterwards they would give them a prescription of plants or whatever it is that they needed. And sometimes the prescription would be to drink ayahuasca, but most of the time it wouldn't be. [27:18]

"You can't separate like DMT, in my eyes, from the rest of the compounds in ayahuasca, from the ceremony, from the jungle. That, in my opinion, is what makes up Shipibo. Otherwise you just have a bunch of chemicals." [28:20]

Links:

Dr. Ruffell's website

Dr. Ruffell on LinkedIn

Dr. Ruffell on Instagram

Onaya website

Onaya Science website

Onaya on LinkedIn

Onaya on Instagram

Previous episode: Can Ayahuasca Heal PTSD? with Former Army Ranger Jesse Gould

Psychedelic Medicine Association

Porangui

In this episode, Dr. Sean M. Viña joins to discuss the ways that social inequality can impact psychedelic healing. Dr. Viña is a sociologist with a PhD from Indiana University whose research focuses on psychedelics and mental health, and social inequality.

In this conversation, Dr. Viña explains that while psychedelics are often framed as transformative treatments, their benefits appear unevenly distributed and frequently constrained by structural factors such as income inequality, education, stigma, caregiving burden, segregation, and social isolation. The discussion highlights how women—particularly single mothers—may experience diminished gains due to caregiving demands and stigmatization of mental illness, while Black and Latino populations show little measurable benefit once socioeconomic inequality is accounted for. Throughout, Dr. Viña emphasizes that outcomes are shaped less by the substances themselves than by the sociocultural environments people return to after treatment, underscoring the importance of community integration and structural supports alongside clinical care.

In this episode, you'll hear:

• What inspired Dr. Viña to research social inequality and psychedelics
• How caregiving burden, education, and stigma modulate women's mental health outcomes following psychedelic use
• Why socioeconomic inequality appears to eliminate measurable benefits for many Black and Latino participants
• The role of segregation, policing environments, and chronic stress in shaping treatment outcomes
• Why American Indian populations respond better to psychedelic treatments in rural areas with greater access to nature and their culture
• How having access to private versus public health insurance can impact psychedelic healing
• Why focusing only on therapist–patient interactions may miss key determinants of success
• Implications for designing more equitable psychedelic treatments and research

Quotes:

"Women who are highly educated actually seem to be getting about as much benefit [from psychedelic treatments] as men who are highly educated, but [lack of] education doesn't seem to negatively affect men the same way it affects women. Again, that's the pattern we see in all kinds of other health resources." [9:36]

"One of the studies that we did showed that if it wasn't for education and income differences, there would be a slight benefit [from psychedelics] for black participants in these surveys. But as soon as you accounted for education inequality and income inequality, it was wiped out." [21:40]

"I love the concept of the psychedelic renaissance, but when we start thinking about the statistics of who this is helping, this is a renaissance of less than 1% of people, right? This is a very small group of people who are getting benefits, just like many of the other resources that have come out in the past. … all these resources are probably valuable. They're all helpful. But there needs to be more than just the drug. There needs to be a bigger conversation about this society and the community that people are living in." [36:31]

Dr. Viña's academic articles:

"Medical Sociological and Epidemiological Psychedelics Paradigm", Drug Science Policy and Law, 2025

"A Community Centered Approach to Psychedelics", Discover Mental Health, 2025

"Unequal Healing: Gender, Psychedelics, and the Burden of Care", Women and Therapy, 2026

"Psychedelics and Mental Health Treatment Seeking Among Asians and Hawaiians", Psychoactives, 2025

"American Indian areas and psychedelics: A test of the minorities' diminished psychedelic returns", Journal of Rural Mental Health, 2025

"Religious Social Integration, Psychedelics, and Psychological Distress", Journal of Psychoactive Drugs, 2024

"Stigma, Psychedelic Use, and the Risk of Reduced Formal Mental Health Care", Stigma and Health, 2024

With Amanda L. Stephens: "Minorities' Diminished Psychedelic Returns." Drug Science, Policy and Law, 2023

Links:

Dr. Viña on LinkedIn

Dr. Viña on Researchgate

Previous episode: Psychedelics and Religion with Hunt Priest, MDiv

Psychedelic Medicine Association

Porangui

In this episode, Hunt Priest joins to discuss the intersection of psychedelic experiences and religion. Hunt is the founder of Ligare: A Christian Psychedelic Society and was a participant in the Johns Hopkins/NYU Psilocybin Study for Religious Leaders in 2016. The epiphanies he had at Hopkins forever changed the trajectory of his work and led him to start Ligare in 2021.

In this conversation, Hunt Priest reflects on how participating in the Johns Hopkins study reshaped his understanding of Christianity, embodiment, and spiritual experience. Drawing on his background as an Episcopal priest, he explores the deep resonance between psychedelic experiences and Christianity, arguing that non-ordinary states of consciousness have always been central to religious life, even if institutional churches have often marginalized them. The discussion ranges from spiritual emergence and theological disruption to healing, discernment, and the role clergy can play in preparation and integration. Hunt also shares his own profound embodied experience during the study where he encountered Vedic and Upanishadic concepts firsthand. He explains how it ultimately led him to found Ligare, a Christian psychedelic society aimed at bridging psychedelics, healing, and the Christian mystical tradition.

In this episode, you'll hear:

• Hunt's ideas of how psychedelic experiences connect with Christian sacraments and liturgical practices
• How psychedelics connect with understandings of religious pluralism and the diversity of spiritual experiences
• Resources for working through ideas that psychedelic experiences could be sinful or demonic
• Hunt's thoughts on navigating theological disruption, spiritual emergence, and expanded images of God
• Why embodiment and bodily wisdom are central to spiritual insight and healing
• The vital opportunity institutional religion risks missing in the current psychedelic renaissance

Quotes:

"I think there's a lot of us [clergy] out there that understand that the spiritual issues that come up with psychedelics are important and need to be tended to in a sensitive way—in an open minded way, an open hearted way." [14:36]

"The Church has, over time, taught people to not trust their minds or their bodies. And that's a huge mistake because our bodies keep the score and they also are one of the places we hold wisdom—which was the biggest lesson I got from the first experience I had at Hopkins." [17:39]

"That's why the spiritual care professionals could be so important: when these issues, these spirit big spiritual questions or even a collapse of your own theological framework happens, you need help to put it back together. And just like therapy helps us put our emotional life back together, I think a good spiritual director or spiritual advisor—one-on-one or small group work—can help us put our theology back together." [21:47]

Links:

Ligare website

Ligare on Instagram

Hunt on Instagram

Hunt on LinkedIn

Center for Action and Contemplation website

Previous episode: Avoiding the Pitfalls of Psychedelic Medicine with Matthew Johnson, PhD

Psychedelic Medicine Association

Porangui

In this encore episode of the Psychedelic Medicine Podcast, psychedelic science researcher and educator Dr. Manesh Girn discusses his studies investigating psychedelic brain action. Manesh earned PhD in neuroscience at McGill University and is an author on over a dozen peer-reviewed articles on psychedelics and related topics. He is also chief research officer at EntheoTech Bioscience and runs the YouTube channel the Psychedelic Scientist.

In this conversation, Manesh discusses his recent article in Trends in Cognitive Sciences titled "A complex systems perspective on psychedelic brain action."He explains the complexity science approach used in the article, which emphasizes the brain is a holistic, interconnected system, rather than individual component networks that can be isolated. From this standpoint, Manesh critiques some simplistic explanations of the neural mechanisms of psychedelics which focus exclusively on interactions with the default mode network isolated from other brain systems.

He also explains how individual some of the neural effects of psychedelics are, citing different findings from different studies and observed variations between brain scans of different people. By better understanding these individual differences, and placing these different responses into a complexity science framework, Manesh believes that more individually-tailored psychedelic therapies are possible once the systems involved are more comprehensively understood.

Manesh closes this discussion by explaining the difference between genuine complexity and sheer chaos. Complexity, he explains, is a delicate balance of novelty and order, which is why psychedelic experiences can be both destabilizing and productive of novel insights and personal transformation.

In this episode:

• The research into psychedelics and the default mode network
• Using frameworks from complexity science in psychedelic research
• Measuring entropy in the brain
• Differences in neurological effects from taking between different studies and different individuals
• How a complexity science approach to neuroscience could better inform precision psychiatry

Quotes:

"You can't just look at a specific brain region or network [in psychedelic research], you've gotta talk about the brain as a whole, in this sense of seeing the brain as a system of interacting parts." [4:49]

"The core idea of this paper is that psychedelics put our brain into this state that is more dynamically flexible, it's more diverse in its activity patterns, and it's more sensitive to inputs that come in." [14:17]

"What we find in the brain imaging findings is that different studies disagree, but also if you look at individual people, they can have radically different effects on their brain—almost opposite." [21:37]

Links:

Manesh' recent article in Trends in Cognitive Sciences: "A complex systems perspective on psychedelic brain action"

​​Psilocybin vs Placebo Brain Connectivity Diagram from Dr. Robin Carhart-Harris

The Psychedelic Scientist YouTube Channel

The Psychedelic Scientist on Instagram

The Psychedelic Scientist on Twitter

Manesh on LinkedIn

EntheoTech website

Psychedelic Medicine Association

Porangui

In this episode, Will Van Derveer, MD joins to unpack what we know about which psychedelic medicines are best suited to particular mental health conditions. Dr. Van Derveer has trained several thousand mental health professionals in psychedelic-assisted psychotherapy, provided ketamine assisted therapy to hundreds of people, and has staffed MDMA therapy trials with MAPS. His book, Psychedelic Therapy: A Revolutionary Approach to Restoring Your Mental Health and Reclaiming Your Life, will be published by Shambala in the spring of 2026.

In this conversation, Dr. Van Derveer offers a clinician's framework for thinking through how different psychedelic medicines may align with different mental health conditions. He explores how factors such as anxiety levels, trauma history, prior psychedelic experience, and a person's orientation toward spiritual versus medical healing shape treatment decisions. Across discussions of anxiety, depression, PTSD, OCD, and eating disorders, Dr. Van Derveer reflects on the relative roles of ketamine, psilocybin, MDMA, and emerging short-acting psychedelics, while underscoring the importance of community, and integration. Throughout, he returns to a central theme: many conditions labeled as psychiatric may also reflect deeper forms of disconnection—social, existential, and spiritual—and psychedelic therapies can be powerful tools for restoring those lost connections when used thoughtfully.

In this episode, you'll hear:

• Why safety, medication interactions, and psychiatric history must come before all other considerations
• The difference between clinical and ceremonial approaches to psychedelic healing
• Considering when group versus individual approaches to psychedelic therapy may be best suited for a particular patient
• How ketamine, psilocybin, and MDMA may play distinct roles in treating anxiety and depression
• Considerations of dose, tolerance, and maintenance sessions for ketamine treatments
• Why MDMA-assisted therapy stands out for chronic and severe PTSD
• Dr. Van Derveer's perspective on emerging psychedelic medicines and the future of treatment

Quotes:

"As time wears on, I lean more toward the group dynamic [for psychedelic therapy] because of the power of community and healing in community. And also, of course, it can help mitigate the cost of access for people." [8:24]

"There's a lot of conversation about ibogaine right now, and I think it's an incredibly powerful, beautiful, sacred, ancient medicine that has a role. But it has a lot more porcupine quills on it than, say, ketamine or MDMA." [27:16]

"In acute suicidality, I think ketamine is the treatment of choice. There's nothing like it. … it can be quite impressive how quickly suicidal thoughts melt away. But it is a short game because often it doesn't stick for people. And that's a huge drawback." [28:39]

"We know that there are clear associations between chronic depression and high levels of inflammation in the body and also in the brain. Ketamine and psilocybin both have strong anti-inflammatory effects. But it seems like somehow the pathways that psilocybin is working on… tends to produce longer term benefits." [30:10]

"I tend to think that spiritual connection—in whatever your language is, whatever your metaphors are, however you think about it—is something that we need to think about for health overall." [40:21]

Links:

Dr. Van Derveer on LinkedIn

Dr. Van Derveer on Instagram

Dr. Van Derveer on X

Dr. Van Derveer's forthcoming book, Psychedelic Therapy: A Revolutionary Approach to Restoring Your Mental Health and Reclaiming Your Life

Integrative Psychiatry Institution website

Previous episode: Is Psilocybin Safe for Me? with Seth Mehr, MD

Psychedelic Medicine Association

Porangui

In this episode, Alicia Bigelow, ND joins to discuss the potential of psychedelic medicine to support the menopause transition. Dr. Ali Bigelow is a naturopathic physician, ketamine provider and licensed psilocybin facilitator in Portland, OR. She leads individual and group retreats, enjoys incorporating live music into her sessions when desired, and is passionate about supporting those navigating life transitions, such as end of life and menopause, through her low dose group, Menomorphosis. Dr. Bigelow will be doing retreats in 2026 with Rise Up Journeys at RiseUpJourneys.com

In this conversation, Dr. Bigelow explores the emerging intersection between psychedelics and the menopausal transition, framing perimenopause and menopause as profound neuroendocrine, psychological, and existential shifts rather than merely clinical syndromes. She also discusses how hormonal changes—particularly declining estrogen—interact with serotonin, inflammation, and neuroplasticity, potentially shaping psychedelic experiences and outcomes. Throughout the discussion, Dr. Bigelow emphasizes the unique capacity of psychedelics to support self-actualization, identity reformation, and meaning-making during midlife, especially when combined with hormone therapy, intentional integration practices, and strong community support.

In this episode, you'll hear:

• Why perimenopause and menopause represent a major but under-recognized neurobiological life transition
• How estrogen, serotonin receptors, and psychedelics like psilocybin may interact in midlife
• What we know (and don't yet know) about hormone replacement therapy and psychedelic efficacy
• The potential anti-inflammatory effects of psychedelics and their relevance to menopausal symptoms
• How ketamine may function differently from classic psychedelics during hormonal transitions
• Why psychedelics can support identity reorientation, self-actualization, and "not caring" in generative ways
• The critical role of community, creativity, and nervous system regulation in integration during midlife

Quotes:

"We don't honor and celebrate aging and elderhood overall in our culture. … What I do feel is really vital is that we gather and support each other in all of life's transitions, and [menopause has] not only been underrepresented, but also just under honored." [3:29]

"As [estrogen] levels decrease, there's a decrease in serotonin receptors—which is the 5-HT2A receptor. And so that reduces our sensitivity to, and activity of serotonin. And psilocybin and LSD and other 5-HT2A agonists—they can enhance their receptors and the activity of those receptors." [13:20]

"The understanding is that with [estrogen] hormone replacement therapy you would then, theoretically, see a replenishment of [serotonin] receptors, and then the psilocybin would have more ability to act on those receptors." [15:37]

"Psilocybin—and psychedelics in general—and the menopausal transition are just really beautiful complements to each other and they become even more potent when used together." [19:48]

Links:

Dr. Bigelow on LinkedIn

Dr. Bigelow on Instagram

Dr. Bigelow's website

Synaptic Institute website

Rise Up Journeys website

Psychedelic Medicine Association

Porangui